Clinical Trial Update: Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating pegylated interferon alfa-2b in combination with low-dose ribavirin for chronic hepatitis C genotype 1 patients with high viral load …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2012-01-18